サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1794636

ポリADPリボースポリメラーゼ（PARP）阻害剤の世界市場

Poly ADP-Ribose Polymerase (PARP) Inhibitors

出版日
ページ情報
英文 284 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.42円
ポリADPリボースポリメラーゼ（PARP）阻害剤の世界市場
出版日: 2025年08月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 284 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ポリADPリボースポリメラーゼ（PARP）阻害剤の世界市場は2030年までに349億米ドルに達する見込み

2024年に108億米ドルと推定されるポリADPリボースポリメラーゼ（PARP）阻害剤の世界市場は、2024年から2030年にかけてCAGR 21.7%で成長し、2030年には349億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである小売薬局は、CAGR23.1%を記録し、分析期間終了時には233億米ドルに達すると予測されます。病院薬局セグメントの成長率は、分析期間でCAGR 19.6%と推定されます。

米国市場は29億米ドルと推定、中国はCAGR29.2％で成長予測

米国のポリADPリボースポリメラーゼ（PARP）阻害剤市場は2024年に29億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに84億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは29.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ17.2%と19.5%と予測されています。欧州では、ドイツがCAGR約18.2%で成長すると予測されています。

世界のポリADPリボースポリメラーゼ（PARP）阻害剤市場- 主要動向と促進要因のまとめ

DNA修復経路を標的とするPARP阻害剤はいかにがん治療のパラダイムを再構築しつつあるか

なぜPARP阻害剤は固形がん管理におけるプレシジョン・オンコロジーに革命をもたらすのか？

ポリADPリボースポリメラーゼ（PARP）阻害剤は、がん細胞のDNA修復機構を破壊し、相同組換え欠損症（HRD）を有する腫瘍の合成致死をもたらす一群の標的がん治療薬です。これらの経口剤は、一本鎖DNA切断の修復に重要な役割を果たすPARP酵素ファミリーを選択的に阻害することにより、機能的なBRCA1/BRCA2や他の修復経路タンパク質を欠く細胞において致死的なDNA損傷を蓄積させる。その結果、正常細胞を温存しながら腫瘍細胞を選択的に死滅させることができ、個別化医療に大きな進歩をもたらします。当初、PARP阻害剤はBRCA変異卵巣がんを適応症として承認されたが、現在では乳がん、前立腺がん、膵臓がん、子宮内膜がんなどに適応を拡大しています。承認された主な薬剤には、オラパリブ（リンパーザ）、ニラパリブ（ゼジュラ）、ルカパリブ（ルブラカ）、タラゾパリブ（タルゼンナ）などがあり、それぞれ独自の薬物動態、毒性プロファイル、投与プロトコルを有しています。これらの治療法は、特にHRD陽性腫瘍患者を対象に、初回治療と維持療法の両方で治療基準を再定義しています。PARP阻害剤の治療上の利点は、従来の化学療法では十分な治療が受けられなかった遺伝的に定義された腫瘍サブタイプに対応できることにあります。経口投与と良好な毒性プロファイルは患者のコンプライアンスをさらに高め、腫瘍ポートフォリオにおける魅力的な選択肢となっています。

PARP阻害剤の世界の普及を牽引しているがん種と患者集団は？

卵巣がんは依然としてPARP阻害剤治療の主要な適応症です。PARP阻害剤による維持療法は、最前線と再発の両方の設定において、BRCA遺伝子変異や広範なHRDシグネチャーを有する患者の無増悪生存期間を有意に延長しています。SOLO-1、PRIMA、ARIEL3などの第III相試験に基づいて、薬事承認が拡大されました。これらの臨床試験により、BRCA遺伝子変異やHRD陽性のサブグループにまたがるPARP阻害剤の有用性が検証され、臨床的有用性が拡大した。乳がん、特に生殖細胞系列のBRCA遺伝子変異を有するトリプルネガティブ腫瘍やHER2陰性腫瘍では、PARP阻害剤は化学療法後の単剤療法または併用療法として支持を得ています。OlympiAD試験とEMBRACA試験は、その有効性を支持する確固たるエビデンスを提供し、転移治療経路への統合につながりました。転移性去勢抵抗性前立腺がん（mCRPC）では、オラパリブやルカパリブなどの薬剤が、特定のDNA損傷修復（DDR）遺伝子変化を有する患者に対して承認され、これらの薬剤の臨床的足跡はさらに拡大しています。膵臓がんは、これまで予後不良で治療の選択肢が限られていたが、PARP阻害剤の新たなフロンティアとして浮上してきました。POLO試験は、BRCA変異腫瘍患者に対する維持療法としてのオラパリブの有用性を実証し、この悪性腫瘍における重要なブレークスルーを示しました。さらに、DNA修復異常が存在する子宮内膜がん、胆管がん、小細胞肺がんにおけるPARPの有効性が、実際のエビデンスやバスケット試験で検討されています。

臨床戦略と併用療法は、PARP阻害剤の有用性をどのように高めているか？

PARP阻害剤をめぐる臨床戦略は急速に進化しており、免疫チェックポイント阻害剤（ICI）、血管新生阻害剤、化学療法との併用療法を評価する試験が進行中です。前臨床データは、PARP阻害がcGAS-STING経路を活性化することにより腫瘍の免疫原性を高め、PD-1/PD-L1遮断の有効性を高めることを示唆しています。MEDIOLAやTOPACIOのような臨床試験では、乳がんや卵巣がんにおけるこの相乗効果を評価しています。ベバシズマブなどのVEGF阻害剤との併用は、特にプラチナ製剤感受性の卵巣がんで有望な結果を示しています。PAOLA-1試験では、オラパリブとベバシズマブの併用がHRD陽性患者のPFSを有意に延長することが示され、BRCA変異腫瘍以外でのPARP阻害剤の使用が支持されています。その他の試験では、プラチナ製剤が奏効した後にPARP阻害剤を使用したり、タキサン系化学療法と同時に使用したりして、臨床的有用性を最適化するシークエンス戦略が検討されています。バイオマーカー開発も進んでいます。BRCA1/2以外にも、ATM、CHEK2、RAD51、PALB2の変化がPARP感受性の予測マーカーとして検証されつつあります。ゲノム不安定性スコアを用いたHRD検査は、適格な患者をより正確に特定するために臨床ワークフローに統合されつつあります。コンパニオン診断薬は、治療法の承認と共に進化しており、薬剤の展開と分子検査インフラを整合させています。

PARP阻害剤の世界的成長を促進する市場促進要因は？

PARP阻害剤市場の成長は、プレシジョン・オンコロジーの拡大、バイオマーカーに基づく患者層別化、BRCA陽性患者の増加など、複数の力が交錯することによってもたらされます。最も大きな推進力のひとつは、個別化がん治療へのパラダイムシフトです。次世代シークエンシング（NGS）ががん治療における標準的な手法となるにつれ、HRD関連変異を持つ患者がより多く同定されるようになり、PARP阻害剤の対処可能な市場が拡大しています。毒性を最小限に抑えた維持療法への需要が、特に卵巣がんや前立腺がんなどのフロントラインでの取り込みを加速させています。さらに、コンパニオン診断薬やバイオマーカーに基づく処方に対する支払者の支援の高まりは、償還のハードルを下げ、地域のがん診療や新興ヘルスケアシステムでの幅広い採用を可能にしています。

また、画期的治療薬の指定、迅速承認、国際的な規制の調和により、市場参入が加速しています。アジア太平洋やラテンアメリカの新興国では、BRCA検査の認知度向上や治療ガイドラインへの組み入れを背景に、PARP阻害剤を国家的ながん対策戦略に組み込もうとしています。PARP阻害剤の商業的展望は、併用レジメン、早期の適応、汎がんバイオマーカー承認がパイプラインを通じて進展するにつれて、持続的成長の態勢が整いつつあります。PARP阻害剤の臨床的汎用性の拡大、経口投与形態、他の標的薬剤との相乗効果により、PARP阻害剤は将来のがん治療薬の中心的存在となると思われます。

セグメント

流通チャネル（小売薬局、病院薬局、オンライン流通チャネル）、エンドユース（卵巣がんエンドユース、乳がんエンドユース、その他エンドユース）

調査対象企業の例

  • AbbVie Inc.
  • Allarity Therapeutics Inc.
  • Artios Pharma
  • AstraZeneca Plc
  • Bayer AG
  • BeiGene Ltd.
  • Clovis Oncology（now part of Bristol Myers Squibb）
  • Daiichi Sankyo Co. Ltd.
  • Everest Pharmaceuticals Ltd.
  • GlaxoSmithKline Plc
  • IMPACT Therapeutics
  • Jeil Pharmaceuticals Co. Ltd.
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Merck & Co., Inc.
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Repare Therapeutics Inc.
  • Zai Lab Ltd.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37767

Global Poly ADP-Ribose Polymerase (PARP) Inhibitors Market to Reach US$34.9 Billion by 2030

The global market for Poly ADP-Ribose Polymerase (PARP) Inhibitors estimated at US$10.8 Billion in the year 2024, is expected to reach US$34.9 Billion by 2030, growing at a CAGR of 21.7% over the analysis period 2024-2030. Retail Pharmacies, one of the segments analyzed in the report, is expected to record a 23.1% CAGR and reach US$23.3 Billion by the end of the analysis period. Growth in the Hospital Pharmacies segment is estimated at 19.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.9 Billion While China is Forecast to Grow at 29.2% CAGR

The Poly ADP-Ribose Polymerase (PARP) Inhibitors market in the U.S. is estimated at US$2.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$8.4 Billion by the year 2030 trailing a CAGR of 29.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.2% and 19.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 18.2% CAGR.

Global Poly ADP-Ribose Polymerase (PARP) Inhibitors Market - Key Trends & Drivers Summarized

Targeting DNA Repair Pathways: How PARP Inhibitors Are Reshaping Cancer Therapy Paradigms

Why Are PARP Inhibitors Revolutionizing Precision Oncology in Solid Tumor Management?

Poly ADP-ribose polymerase (PARP) inhibitors are a class of targeted cancer therapies that disrupt DNA repair mechanisms in cancer cells, leading to synthetic lethality in tumors with homologous recombination deficiencies (HRD). These oral agents selectively inhibit the PARP enzyme family-key players in repairing single-strand DNA breaks-thereby allowing lethal DNA damage to accumulate in cells lacking functional BRCA1/BRCA2 or other repair pathway proteins. The result is selective tumor cell death while sparing normal cells, offering a significant advancement in personalized medicine. Initially approved for BRCA-mutated ovarian cancer, PARP inhibitors have expanded into indications including breast, prostate, pancreatic, and endometrial cancers. Major approved agents include olaparib (Lynparza), niraparib (Zejula), rucaparib (Rubraca), and talazoparib (Talzenna), each with unique pharmacokinetics, toxicity profiles, and dosing protocols. These therapies have redefined treatment standards in both first-line and maintenance settings, particularly for patients with HRD-positive tumors. The therapeutic advantage of PARP inhibitors lies in their capacity to address genetically defined tumor subtypes that were previously underserved by conventional chemotherapy. Their oral administration and favorable toxicity profiles further enhance patient compliance, making them an attractive option in oncology portfolios.

Which Cancer Types and Patient Populations Are Driving the Adoption of PARP Inhibitors Globally?

Ovarian cancer remains the leading indication for PARP inhibitor therapy. In both frontline and recurrence settings, maintenance therapy with PARP inhibitors has significantly extended progression-free survival in patients with BRCA mutations or broader HRD signatures. Regulatory approvals have been expanded based on Phase III trials such as SOLO-1, PRIMA, and ARIEL3. These trials have validated the benefit of PARP inhibitors across BRCA-mutated and HRD-positive subgroups, broadening their clinical utility. In breast cancer, particularly triple-negative and HER2-negative tumors with germline BRCA mutations, PARP inhibitors have gained traction as monotherapy or combination therapy following chemotherapy. The OlympiAD and EMBRACA trials have provided robust evidence supporting their efficacy, leading to their integration into metastatic treatment pathways. In metastatic castration-resistant prostate cancer (mCRPC), agents like olaparib and rucaparib have been approved for patients with specific DNA damage repair (DDR) gene alterations, further expanding the clinical footprint of these agents. Pancreatic cancer, historically associated with poor prognosis and limited treatment options, has emerged as a new frontier for PARP inhibitors. The POLO trial demonstrated the utility of olaparib as a maintenance therapy for patients with BRCA-mutated tumors, representing a significant breakthrough in this notoriously aggressive malignancy. Additionally, real-world evidence and basket trials are exploring PARP efficacy in endometrial, bile duct, and small cell lung cancers where DNA repair defects are present.

How Are Clinical Strategies and Combination Therapies Enhancing PARP Inhibitor Utility?

The clinical strategy around PARP inhibitors is evolving rapidly with ongoing trials assessing their use in combination with immune checkpoint inhibitors (ICIs), anti-angiogenic agents, and chemotherapy. Preclinical data suggest that PARP inhibition increases tumor immunogenicity by activating cGAS-STING pathways, thereby enhancing the efficacy of PD-1/PD-L1 blockade. Trials like MEDIOLA and TOPACIO are evaluating this synergy in breast and ovarian cancers. Combination with VEGF inhibitors such as bevacizumab has shown promising outcomes, particularly in platinum-sensitive ovarian cancer. The PAOLA-1 trial demonstrated that olaparib plus bevacizumab extended PFS significantly in HRD-positive patients, supporting the use of PARP inhibitors beyond BRCA-mutated tumors. Additionally, studies are investigating sequencing strategies-using PARP inhibitors after platinum response or concurrently with taxane-based chemotherapy-to optimize clinical benefit. Biomarker development is also advancing. Beyond BRCA1/2, alterations in ATM, CHEK2, RAD51, and PALB2 are being validated as predictive markers of PARP sensitivity. HRD testing using genomic instability scores is being integrated into clinical workflows to identify eligible patients more accurately. Companion diagnostics are co-evolving with therapy approvals, aligning drug deployment with molecular testing infrastructure.

What Market Drivers Are Propelling the Global Growth of PARP Inhibitors?

The growth in the PARP inhibitors market is driven by multiple intersecting forces including precision oncology expansion, biomarker-based patient stratification, and increasing prevalence of BRCA-tested patients. One of the foremost drivers is the paradigm shift toward personalized cancer therapy. As next-generation sequencing (NGS) becomes standard practice in oncology, more patients are being identified with HRD-related mutations, expanding the addressable market for PARP inhibitors. The demand for maintenance therapies with minimal toxicity is accelerating uptake in frontline settings, particularly in ovarian and prostate cancers. Additionally, growing payer support for companion diagnostics and biomarker-guided prescribing is reducing reimbursement hurdles, enabling broader adoption across community oncology practices and emerging healthcare systems.

Regulatory support is also robust, with breakthrough therapy designations, fast-track approvals, and international regulatory harmonization accelerating market entry. Emerging economies in Asia-Pacific and Latin America are incorporating PARP inhibitors into national cancer control strategies, driven by rising awareness of BRCA testing and inclusion in treatment guidelines. As combination regimens, earlier-line indications, and pan-cancer biomarker approvals progress through pipelines, the commercial outlook for PARP inhibitors is poised for sustained growth. Their expanding clinical versatility, oral delivery format, and synergy with other targeted agents make them central to the future of oncology therapeutics.

SCOPE OF STUDY:

The report analyzes the Poly ADP-Ribose Polymerase (PARP) Inhibitors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Distribution Channel); End-Use (Ovarian Cancer End-Use, Breast Cancer End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

  • AbbVie Inc.
  • Allarity Therapeutics Inc.
  • Artios Pharma
  • AstraZeneca Plc
  • Bayer AG
  • BeiGene Ltd.
  • Clovis Oncology (now part of Bristol Myers Squibb)
  • Daiichi Sankyo Co. Ltd.
  • Everest Pharmaceuticals Ltd.
  • GlaxoSmithKline Plc
  • IMPACT Therapeutics
  • Jeil Pharmaceuticals Co. Ltd.
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Merck & Co., Inc.
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Repare Therapeutics Inc.
  • Zai Lab Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Ovarian and Breast Cancers Expands Addressable Market for PARP Inhibitors
    • Growing Use of PARP Inhibitors in Precision Oncology Strengthens Business Case for Targeted Therapies
    • FDA and EMA Approvals of New Indications Propel Commercial Uptake Across Oncology Segments
    • Expansion of Companion Diagnostics Throws the Spotlight on Biomarker-Driven Treatment Protocols
    • Ongoing Clinical Trials in Prostate and Pancreatic Cancers Drive Indication Pipeline Diversification
    • Integration With Immuno-Oncology and Combination Therapies Enhances Treatment Efficacy
    • Rising Healthcare Spending in Emerging Markets Accelerates Global Access to PARP Inhibitors
    • Strategic Collaborations Between Pharma and Diagnostic Companies Fuel Development Synergies
    • Growth in Germline and Somatic Mutation Testing Supports Patient Stratification and Adoption
    • Patent Expiries and Generic Entry Pose Pricing Pressure and Market Disruption Risks
    • Increasing Reimbursement Approvals Across Oncology Centers Sustain Treatment Adoption
    • Technological Advancements in Drug Delivery Systems Improve Bioavailability and Patient Compliance
    • Focus on Long-Term Survival and Maintenance Therapies Drives Repeat Treatment Cycles
    • Regulatory Fast-Tracking of Breakthrough Therapies Enhances Speed-to-Market for New Entrants
    • Rise in Awareness Programs for BRCA-Mutated Cancers Strengthens Patient Outreach Efforts
    • Investments in Real-World Evidence and Outcome Studies Bolster Market Positioning
    • Expansion of Hospital-Based Oncology Infrastructure Promotes Institutional Procurement
    • Integration Into National Cancer Control Programs Facilitates Widespread Adoption
    • Pharmacovigilance and Post-Marketing Surveillance Requirements Create Compliance Complexity
    • Emerging Applications in Rare and Orphan Oncology Indications Unlock Niche Market Potential
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Ovarian Cancer End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Ovarian Cancer End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Ovarian Cancer End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Breast Cancer End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Breast Cancer End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Breast Cancer End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Poly ADP-Ribose Polymerase (PARP) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Poly ADP-Ribose Polymerase (PARP) Inhibitors by End-Use - Percentage Breakdown of Value Sales for Ovarian Cancer End-Use, Breast Cancer End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION